Federal regulators have begun a safety review of two RSV medicines used to protect infants, even though no safety problems ...

U.S. health regulators informed senior executives at Merck, Sanofi and AstraZeneca last week that their approved protective RSV treatments for infants would face fresh safety scrutiny following ...

As an FDA official said that the agency has evidence that links COVID vaccines to the deaths of at least 10 children, the U.S ...

The FDA reportedly told drugmakers that approved monoclonal antibodies to protect infants against respiratory syncytial virus ...

FDA officials are newly scrutinizing several approved therapies to treat RSV in babies despite the fact that these shots were shown to be safe in clinical trials ...

In this morning's Pharmalittle roundup, we're reading about FDA scrutiny of RSV therapies, an AI tool for clinical trials, ...

Among adults older adults, a respiratory syncytial virus (RSV) infection increases the risk of cardiovascular events over the ...

FDA turns up the heat: Federal regulators are requesting more safety information from drugmakers on products meant to protect ...

GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) ...

Respiratory syncytial virus, commonly known as RSV, is often associated with cold-like symptoms in young children.

In a new study, adults 45 and up who got this seasonal virus had a higher risk of major heart issues, especially in the first ...

A new study has found that a significant percentage of adults in the United States have at least one risk factor for severe respiratory syncytial virus (RSV), even as eligibility for the RSV ...